**Core Concept**
Esmolol is an ultra-short-acting beta-blocker with a unique pharmacokinetic profile, primarily used in clinical settings for controlling heart rate in various cardiac conditions, including supraventricular tachycardia, acute myocardial infarction, and perioperative hypertension. Its rapid onset and short duration of action make it an ideal choice for titration and short-term use.

**Why the Correct Answer is Right**
Esmolol is classified as a cardioselective β1-blocker, which means it preferentially blocks the β1-adrenergic receptors in the heart, leading to a decrease in heart rate and contractility. This property allows it to reduce the sympathetic tone without causing significant bronchoconstriction or peripheral vasoconstriction. The mechanism of esmolol involves competitive inhibition of β1-adrenergic receptors, leading to a decrease in the heart rate and cardiac output.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because, although esmolol is a beta-blocker, the term "cardioselective" is more accurately applied to drugs like metoprolol, which have a higher affinity for β1-receptors compared to β2-receptors. Esmolol is often considered a more β1-selective beta-blocker, but the term is not typically used to describe it.

**Option B:** Incorrect because esmolol does not increase airway resistance. In fact, its cardioselective action reduces the risk of bronchoconstriction associated with non-selective beta-blockers.

**Option C:** Incorrect because esmolol is actually used to decrease heart rate, not increase it. Its negative chronotropic effect is a result of its action on β1-adrenergic receptors.

**Option D:** Incorrect because esmolol's half-life is approximately 9 minutes, which makes it an ultra-short-acting beta-blocker. This unique property allows for rapid titration and short-term use.

**Option E:** Incorrect because esmolol has negative chronotropic activity, which refers to its ability to decrease heart rate. However, its inotropic activity (the contractility of the heart) is not significantly affected, making it a more suitable choice for patients with compromised cardiac function.

**Clinical Pearl / High-Yield Fact**
Esmolol's ultra-short-acting profile and cardioselective action make it an ideal choice for managing perioperative hypertension and controlling heart rate in critically ill patients. Its use should be carefully titrated to avoid excessive bradycardia or hypotension.

**Correct Answer: a) It is a cardioselective β–blocker**